Advances in Structure-Based Drug Discovery
September 9 - 11, 2007 | Hyatt Regency Airport | San Francisco, CA
Chairs Charles Reynolds of Johnson & Johnson, Dagmar Ringe of Brandeis University, and Kenneth Merz of the University of Florida have combined efforts again to create the second ACS ProSpectives conference dedicated to structure-based drug design.
The goal of this conference is to provide a venue for structural biologists, computational chemists, and medicinal chemists to hear the latest developments in the application of structure to drug discovery. The two-day program will feature leading industrial and academic researchers describing the latest experimental and computational approaches for determining protein target structures and applying those structures to drug discovery.
Examples of topics that will be covered include:
- X-ray and NMR structure determination,
- Homology modeling,
- Structure-based modeling,
- Structure-based ADMET,
- Fragment-based drug discovery, and
- The medicinal chemistry of structure-based design.
In addition, numerous case studies will be given that demonstrate how structure-based design can be used effectively in medicinal chemistry programs.
A full-day short course that covers both "Fundamental Concepts in Computational Chemistry & Computer-Assisted Drug Design" and an "Introduction to Crystallography for the Pharmaceutical Industry" will be offered on Sunday, September 9 (please see Short Course in the right hand navigation column).
Confirmed speakers - for titles and abstracts of their presentations, please click on "Speakers" in the right hand navigation column:
- Keynote: Roger Bone, Senior Vice-President Research and Early Development, Johnson & Johnson Pharmaceutical R&D
- William Roush, Executive Director of Medicinal Chemistry, Professor of Chemistry and Associate Dean of the Graduate Program Scripps Florida
- Thomas Tucker, Senior Research Fellow, Medicinal Chemistry, Merck
- Michelle Browner, Vice-President, Discovery Sciences & Technologies, Roche
- Robert Volkmann, Pfizer
- Alexander Tropsha, Professor and Chair, Division of Medicinal Chemistry and Natural Products, University of North Carolina at Chapel Hill
- James Edwards, Senior Research Fellow, Team Leader for Immunology, Johnson & Johnson Pharmaceutical R&D
- Kenneth Merz, Jr., Professor, University of Florida
- Keith W. Woods, Chemistry Research Investigator, Abbott Laboratories
- Richard Friesner, Professor, Columbia University
- Gregory Petsko, Professor, Brandeis University
- Linus Lin, Senior Research Fellow, Merck
- Lance Stewart, Vice-President, DeCODE Biostructures
- James R. Arnold, AstraZeneca
- Wim Hol, Professor, University of Washington
- Eddy Arnold, Rutgers University
"
